It all began with a reunion at the 2009 COA Academic Conference in Xiamen, where the President of the European Association of Tissue Banks put forward the forward‑looking view that “Synthetic bone graft would become an important direction for future bone repair materials”. Firm to this vision, our team embarked on 16 years of exploration and research. In 2026，Wuhan Leader Med‑Biotechnology Co., Ltd. Launched its independently developed bone defect repair material, Porous Bioceramic Bone Substitute, which was approved for market launch in February 2026 (NMPA Registration No. 20263130394). This milestone marks a new chapter in the innovation of bone repair materials.

In the fields of bone tissue reconstruction and soft tissue repair, β‑tricalcium phosphate (β‑TCP) is widely recognized as a high‑performance biomaterial for regenerative applications. Leader Med‑Biotech has independently developed spherical porous β‑TCP microspheres, overcoming the application limitations of traditional block shaped and irregular granular materials. Supported by a comprehensive range of NMPA medical device regulatory qualifications, the microspheres provide a reliable core raw materials for the R&D and mass production of regenerative medical devices.

In the field of orthopedic clinical bone defect repair, the choice of raw materials directly determines product performance and therapeutic outcomes. High‑purity β‑tricalcium phosphate (β‑TCP) offers three key advantages as follows

Bone defect repair and bone tissue regeneration have long been key areas of focus in orthopedics, dentistry and regenerative medicine. Traditional bone repair materials still face significant challenges in terms of degradation rate, osteointegration and osteogenic performance.

The multicenter clinical trial for Absorbable Bone Wound Hemostasis Mud (ABHM), jointly developed by our company and Zhongnan Hospital of Wuhan University, has recently been successfully completed. As of last week, a total of 218 clinical cases had been performed across participating clinical centers, with full data collection and follow-up for all cases expected to be finalized by next week.

August 9, 2025 — At the Hubei Medical Technology Innovation Achievements Conference, hosted by China Media Group (CMG) and held this morning at 10:00 AM, a breakthrough product—Absorbable Bone Wound Hemostasis Mud (ABHM) —was unveiled as a key innovation.

From June 9 to 12, 2025, the 29th China International Exhibition on Dental Exhibition & Scientific Conference (Sino-Dental 2025) was held at the Beijing National Convention Center. Leader Med-Biotech participated in grand style, showcasing its core products at this premier event.

March 22–25, 2025, Shenyang — The 26th China Northeast International Dental Exhibition (CNDE), a UFI-approved international event, kicked off at the Shenyang International Exhibition Center from March 22 to 25.

We sincerely invite you to attend the 2025 South China Dental Expo, which will grandly open on March 3, 2025. The exhibition will run from March 3 to March 6. We are honored to be invited to participate and are currently in full swing preparing for the event.

On July 24, 2024, Wuhan Leader Med-Biotech Co., Ltd. successfully obtained the Chinese Medical Device Registration Certificate (Registration No. 20243171320) for its independently developed Natural Calcined Bone Graft Material. This approval marks another significant milestone in our journey within the healthcare sector.